Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na\(^+/\)H\(^+\) exchanger, lowering of cytosolic Na\(^+\) and vasodilation

Laween Uthman 1 · Antonius Baartscheer 2 · Boris Bleijlevens 3 · Cees A. Schumacher 2 · Jan W. T. Fiolet 2 · Anneke Koenman 1 · Milena Jancev 1 · Markus W. Hollmann 1 · Nina C. Weber 1 · Ruben Coronel 2 · Coert J. Zuurbier 1

Received: 5 October 2017 / Accepted: 1 November 2017 / Published online: 2 December 2017
© The Author(s) 2017. This article is an open access publication

Abstract
Aims/hypothesis Sodium–glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) constitute a novel class of glucose-lowering (type 2) kidney-targeted agents. We recently reported that the SGLT2i empagliflozin (EMPA) reduced cardiac cytosolic Na\(^+\) ([Na\(^+\)]\(_c\)) and cytosolic Ca\(^2+\) ([Ca\(^{2+}\)]\(_c\)) concentrations through inhibition of Na\(^+\)/H\(^+\) exchanger (NHE). Here, we examine (1) whether the SGLT2i dapagliflozin (DAPA) and canagliflozin (CANA) also inhibit NHE and reduce [Na\(^+\)]\(_c\); (2) a structural model for the interaction of SGLT2i to NHE; (3) to what extent SGLT2i affect the haemodynamic and metabolic performance of isolated hearts of healthy mice.

Methods Cardiac NHE activity and [Na\(^+\)]\(_c\) in mouse cardiomyocytes were measured in the presence of clinically relevant concentrations of EMPA (1 \(\mu\)mol/l), DAPA (1 \(\mu\)mol/l), CANA (3 \(\mu\)mol/l) or vehicle. NHE docking simulation studies were applied to explore potential binding sites for SGTL2i. Constant-flow Langendorff-perfused mouse hearts were subjected to SGLT2i for 30 min, and cardiovascular function, O\(_2\) consumption and energetics (phosphocreatine (PCr)/ATP) were determined.

Results EMPA, DAPA and CANA inhibited NHE activity (measured through low pH recovery after NH\(_4\)^+ pulse: EMPA 6.69 ± 0.09, DAPA 6.77 ± 0.12 and CANA 6.80 ± 0.18 vs vehicle 7.09 ± 0.09; \(p<0.001\) for all three comparisons) and reduced [Na\(^+\)]\(_c\) (in mmol/l: EMPA 10.0 ± 0.5, DAPA 10.7 ± 0.7 and CANA 11.0 ± 0.9 vs vehicle 12.7 ± 0.7; \(p<0.001\)). Docking studies provided high binding affinity of all three SGLT2i with the extracellular Na\(^+\)-binding site of NHE. EMPA and CANA, but not DAPA, induced coronary vasodilation of the intact heart. PCr/ATP remained unaffected.

Conclusions/interpretation EMPA, DAPA and CANA directly inhibit cardiac NHE flux and reduce [Na\(^+\)]\(_c\), possibly by binding with the Na\(^+\)-binding site of NHE-1. Furthermore, EMPA and CANA affect the healthy heart by inducing vasodilation. The [Na\(^+\)]\(_c\)-lowering class effect of SGLT2i is a potential approach to combat elevated [Na\(^+\)]\(_c\) that is known to occur in heart failure and diabetes.

Keywords Cardiac · Diabetes · Heart failure · Na\(^+\)/H\(^+\) exchanger · SGLT2i · Sodium · Vasodilation

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00125-017-4509-7) contains peer-reviewed but unedited supplementary material, which is available to authorised users.

Coert J. Zuurbier
c.j.zuurbier@amc.uva.nl

Laween Uthman, Antonius Baartscheer and Boris Bleijlevens contributed equally to this study.

1 Laboratory of Experimental Intensive Care and Anaesthesiology, Department of Anaesthesiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands
2 Department of Clinical and Experimental Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
3 Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
Abbreviations

[Ca2+]c Cytosolic Ca2+ concentration
CANA Canagliflozin
DAPA Dapagliflozin
EMPA Empagliflozin
[Na+]c Cytosolic Na+ concentration
NHE Na+/H+ exchanger
PCr Phosphocreatine
SGLT2 Sodium–glucose cotransporter 2
SGLT2i Sodium–glucose cotransporter 2 inhibitor(s)

Introduction

Sodium–glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) are a new class of type 2 diabetic agents that control plasma glucose levels by inhibiting reabsorption of glucose and sodium in the proximal tubules of the kidney [1]. Of the several different SGLT2i, empagliflozin (EMPA) and canagliflozin (CANA) have shown cardiovascular benefits in type 2 diabetic individuals, with a remarkable 35% and 32% reduction, respectively, in hospitalisation for heart failure [2, 3]. These effects could not be explained by a decline in general cardiovascular risk factors, such as glycaemic status, hypertension or atherosclerosis.

We recently reported direct cardiac effects of EMPA [4]. EMPA lowers cytosolic Na+ ([Na+]c) and cytosolic Ca2+ ([Ca2+]c) concentrations, while increasing mitochondrial Ca2+ concentrations, through inhibition of the myocardial Na+/H+ exchanger (NHE) in isolated rabbit and rat ventricular cardiomyocytes. Both increased [Na+]c and upregulated NHE activity have been shown to contribute to heart failure and diabetes [5–9]. We therefore hypothesised that these cardiac effects of NHE inhibition constituted a causal mechanism for the beneficial clinical effects of EMPA. It is not known whether NHE inhibition is a drug-specific effect of EMPA or a class effect of SGLT2i. Furthermore, molecular binding between SGLT2i and NHE has to our knowledge not been studied. Additionally, no data are available on the direct cardiac effects of SGLT2i on the healthy heart. We therefore studied cardiac NHE activity and [Na+]c in mouse cardiomyocytes for the SGLT2i EMPA, dapagliflozin (DAPA) and CANA and performed docking studies to identify possible binding sites of SGLT2i on NHE. In addition, we studied whether there were direct cardiac haemodynamic and metabolic effects of these SGLT2i on the healthy intact heart.

Methods

A detailed description of the methodology is available in the electronic supplementary material (ESM) Methods.

Animal handling of C57Bl/6NCrl male mice was in accordance with the Institutional Animal Care and Use Committee of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands, and was conducted following the Guide for the Use and Care of Laboratory Animals. Freshly isolated ventricular cardiomyocytes were subjected to 1 μmol/l EMPA, 1 μmol/l DAPA, 3 μmol/l CANA or vehicle (0.02% DMSO [vol./vol.]). These concentrations were based on the maximum plasma concentration of each drug found in vivo at clinically relevant doses [10]. NHE activity was quantified from recovery of pH following an acidifying NH4+ pulse with the use of seminaphtharhodafluor (SNARF) fluorescence. [Na+]c was detected using the sodium-binding benzofuran isophthalate 1 (SBFI-1) fluorescent probe.

A homology model of the protein structure of human NHE-1 was prepared using a bacterial NHE protein structure as a template. Molecular docking studies were performed using the AutoDock Vina software package [11] to explore possible interactions between NHE and SGLT2i.

Langendorff constant-flow perfused mouse hearts were subjected to SGLT2i (at the same concentrations as mentioned above) for 30 min, during which cardiac haemodynamics were monitored. O2 consumption was determined (at t = 25 min following the start of drug infusion) from the difference between coronary influent and effluent O2 levels, and was normalised for heart dry weight and coronary flow. ATP and phosphocreatine (PCr) levels were spectrophotometrically determined in snap-frozen and freeze-dried hearts.

All data were tested for normality using the Kolmogorov–Smirnov test. Normally distributed data were statistically tested by one-way ANOVA with Dunnett’s post hoc tests and were presented as mean ± SD. Not normally distributed data (median, interquartile range), including data for cardiac O2 consumption and energetics of healthy hearts, were tested with the Kruskal–Wallis test; post hoc analysis was conducted with Mann–Whitney U tests and Bonferroni correction. All tests were carried out using the SPSS statistics 24 package (IBM SPSS, Armonk, NY, USA). A p value below 0.05 was considered statistically significant.

Results

SGLT2i can bind to NHE, block NHE activity and reduce [Na+]c in cardiomyocytes

We investigated whether SGLT2i exhibited similar effects on NHE by studying intracellular Na+ and pH. Figure 1a shows reduced recovery of intracellular pH after NH4+ pulse with all three SGLT2i (EMPA 6.69 ± 0.09, DAPA 6.77 ± 0.12 and CANA 6.80 ± 0.18 vs vehicle 7.09 ± 0.09; p < 0.001 for all three comparisons). Furthermore, [Na+]c was reduced with all three SGLT2i (Fig. 1b) after 10 min (in mmol/l: EMPA 10.0 ± 0.5, DAPA 10.7 ± 0.7 and CANA 11.0 ± 0.9 vs vehicle 12.7 ± 0.7; p < 0.001 for all three comparisons).

Interactions between SGLT2i and NHE were explored using a homology model of NHE. The extracellular part of the protein

\[
\text{EMPA lowers cytosolic Na}^+ (\text{[Na}^+\text{]}_c) \text{ and cytosolic Ca}^{2+} (\text{[Ca}^{2+}\text{]}_c) \text{ concentrations, while increasing mitochondrial Ca}^{2+} \text{ concentrations, through inhibition of the myocardial Na}^+/{H}^+ \text{ exchanger (NHE) in isolated rabbit and rat ventricular cardiomyocytes. Both increased [Na}^+\text{]}_c \text{ and upregulated NHE activity have been shown to contribute to heart failure and diabetes [5–9]. We therefore hypothesised that these cardiac effects of NHE inhibition constituted a causal mechanism for the beneficial clinical effects of EMPA. It is not known whether NHE inhibition is a drug-specific effect of EMPA or a class effect of SGLT2i. Furthermore, molecular binding between SGLT2i and NHE has to our knowledge not been studied. Additionally, no data are available on the direct cardiac effects of SGLT2i on the healthy heart. We therefore studied cardiac NHE activity and [Na}^+\text{]}_c \text{ in mouse cardiomyocytes for the SGLT2i EMPA, dapagliflozin (DAPA) and CANA and performed docking studies to identify possible binding sites of SGLT2i on NHE. In addition, we studied whether there were direct cardiac haemodynamic and metabolic effects of these SGLT2i on the healthy intact heart.}
\]

\[
\text{Abbreviations}
\]

- **[Ca2+]c**: Cytosolic Ca2+ concentration
- **CANA**: Canagliflozin
- **DAPA**: Dapagliflozin
- **EMPA**: Empagliflozin
- **[Na+]c**: Cytosolic Na+ concentration
- **NHE**: Na+/H+ exchanger
- **PCr**: Phosphocreatine
- **SGLT2**: Sodium–glucose cotransporter 2
- **SGLT2i**: Sodium–glucose cotransporter 2 inhibitor(s)

\[
\text{Methods}
\]

A detailed description of the methodology is available in the electronic supplementary material (ESM) Methods.

Animal handling of C57Bl/6NCrl male mice was in accordance with the Institutional Animal Care and Use Committee of the Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands, and was conducted following the Guide for the Use and Care of Laboratory Animals. Freshly isolated ventricular cardiomyocytes were subjected to 1 μmol/l EMPA, 1 μmol/l DAPA, 3 μmol/l CANA or vehicle (0.02% DMSO [vol./vol.]). These concentrations were based on the maximum plasma concentration of each drug found in vivo at clinically relevant doses [10]. NHE activity was quantified from recovery of pH following an acidifying NH4+ pulse with the use of seminaphtharhodafluor (SNARF) fluorescence. [Na+]c was detected using the sodium-binding benzofuran isophthalate 1 (SBFI-1) fluorescent probe.

A homology model of the protein structure of human NHE-1 was prepared using a bacterial NHE protein structure as a template. Molecular docking studies were performed using the AutoDock Vina software package [11] to explore possible interactions between NHE and SGLT2i.

Langendorff constant-flow perfused mouse hearts were subjected to SGLT2i (at the same concentrations as mentioned above) for 30 min, during which cardiac haemodynamics were monitored. O2 consumption was determined (at t = 25 min following the start of drug infusion) from the difference between coronary influent and effluent O2 levels, and was normalised for heart dry weight and coronary flow. ATP and phosphocreatine (PCr) levels were spectrophotometrically determined in snap-frozen and freeze-dried hearts.

All data were tested for normality using the Kolmogorov–Smirnov test. Normally distributed data were statistically tested by one-way ANOVA with Dunnett’s post hoc tests and were presented as mean ± SD. Not normally distributed data (median, interquartile range), including data for cardiac O2 consumption and energetics of healthy hearts, were tested with the Kruskal–Wallis test; post hoc analysis was conducted with Mann–Whitney U tests and Bonferroni correction. All tests were carried out using the SPSS statistics 24 package (IBM SPSS, Armonk, NY, USA). A p value below 0.05 was considered statistically significant.

\[
\text{Results}
\]

SGLT2i can bind to NHE, block NHE activity and reduce [Na+]c in cardiomyocytes

We investigated whether SGLT2i exhibited similar effects on NHE by studying intracellular Na+ and pH. Figure 1a shows reduced recovery of intracellular pH after NH4+ pulse with all three SGLT2i (EMPA 6.69 ± 0.09, DAPA 6.77 ± 0.12 and CANA 6.80 ± 0.18 vs vehicle 7.09 ± 0.09; p < 0.001 for all three comparisons). Furthermore, [Na+]c was reduced with all three SGLT2i (Fig. 1b) after 10 min (in mmol/l: EMPA 10.0 ± 0.5, DAPA 10.7 ± 0.7 and CANA 11.0 ± 0.9 vs vehicle 12.7 ± 0.7; p < 0.001 for all three comparisons).

Interactions between SGLT2i and NHE were explored using a homology model of NHE. The extracellular part of the protein...
model was probed to gain insight into the possible binding mode of SGLT2i to NHE. All three SGLT2i displayed high binding affinity to the extracellular Na⁺-binding site of NHE (in kJ/mol: EMPA −34.3, DAPA −32.2, CANA −37.2) and adopted similar binding conformation with the glucoside moiety oriented towards the Na⁺-binding site and the aglycone part of the inhibitors lining the side of the extracellular aperture (Fig. 1c). Binding of a glucose molecule to the NHE homology model showed that glucose bound in an identical orientation to the glucoside part of the SGLT2i, but with a reduced affinity of −24.3 kJ/mol, illustrating the importance of the hydrophobic part of the SGLT2i to ensure efficient binding.

Combined, these data show that EMPA, DAPA and CANA inhibit NHE activity through binding to the Na⁺-binding site of NHE-1. Secondary to this, they reduce [Na⁺]c in isolated cardiomyocytes.

**Discussion**

This study demonstrates for the first time that (1) EMPA, DAPA and CANA inhibit cardiac NHE and reduce [Na⁺]c in cardiomyocytes; (2) EMPA, DAPA and CANA display high binding affinity to the extracellular Na⁺-binding site of NHE; (3) EMPA and CANA cause vasodilation in the isolated healthy heart. The effects of EMPA, DAPA and CANA on cardiac [Na⁺]c through NHE inhibition can therefore be considered a common class effect of SGLT2i. Knowing that elevated [Na⁺]c is a common denominator and driver of diabetes and heart failure [9, 12], we propose that the potential of SGLT2i to lower cardiac [Na⁺]c contributes to reduced heart failure-related hospitalisation, as observed in the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial and the Canagliflozin Cardiovascular Assessment Study (CANVAS) [2, 3]. Further studies are necessary to examine this hypothesis.
EMPA, CANA and DAPA all inhibit NHE activity, reduce \([\text{Na}^+]_c\), and show high binding energy with NHE. Our experiments examining NHE activity and \([\text{Na}^+]_c\) in cardiomyocytes showed that the inhibitory effect on cardiac NHE is not specific to EMPA but extends to other SGLT2i. In our previous work [4], we showed that EMPA treatment not only lowers \([\text{Na}^+]_c\) but reduces \([\text{Ca}^{2+}]_c\) and increases mitochondrial \(\text{Ca}^{2+}\). Since DAPA and CANA also inhibit NHE activity and reduce \([\text{Na}^+]_c\), we postulate that these SGLT2i reduce \([\text{Ca}^{2+}]_c\) and increase mitochondrial \(\text{Ca}^{2+}\) similar to EMPA, and ultimately optimise cardiac mitochondrial function and energetics.

Because both \([\text{Na}^+]_c\) and NHE activity are increased in diabetic and failing hearts, SGLT2i should have an even stronger effect on these in diseased cardiomyocytes. Furthermore, preclinical studies with known NHE inhibitors have clearly shown reductions in the development of hypertrophy and heart failure [13, 14], which support NHE inhibition and its consequential \([\text{Na}^+]_c\)-lowering as a potential class effect of SGLT2i to combat heart failure.

SGLT2i are targeted to SGLT2 by the glucosyl part of the molecule, while binding affinity is determined by the attached hydrophobic moiety. Our docking studies indicate that the hydrophilic glucosyl part of the SGLT2i orients towards the hydrophilic \(\text{Na}^+\)-binding site. The composition of the hydrophobic aglycone part of the SGLT2i appears to be an important determinant in their binding to NHE. The NHE molecule exists in a low- and high-affinity form for intracellular protons, regulated by pH and mitogens [15]. This conformational heterogeneity may be essential in SGLT2i binding, especially in disease states where NHE activity threshold is shifted towards its high-affinity form.

**Vasodilation by SGLT2i in the healthy heart** Our data on isolated mice hearts revealed a direct vasodilation effect of EMPA and CANA, but not DAPA, at constant glucose concentration. Oelze et al [16] have previously shown that EMPA normalised endothelial function in aortic rings from streptozotocin-induced rat models of diabetes, an effect that was also detected with ipragliflozin in a similar mouse model [17]. However, because EMPA treatment in these studies also caused a large reduction in plasma glucose levels, it is impossible to interpret these data towards EMPA exerting direct vascular effects. Wang et al [18] reported that NHE activation in hyperglycaemic endothelial cells led to increased intracellular \(\text{Ca}^{2+}\) and reduced endothelial nitric oxide synthase levels and impaired relaxation of aortic rings from streptozotocin-induced rat models of diabetes, an effect that was also detected with ipragliflozin in a similar mouse model [17]. However, because EMPA treatment in these studies also caused a large reduction in plasma glucose levels, it is impossible to interpret these data towards EMPA exerting direct vascular effects. Wang et al [18] reported that NHE activation in hyperglycaemic endothelial cells led to increased intracellular \(\text{Ca}^{2+}\) and reduced endothelial nitric oxide synthase levels and impaired relaxation of aortic rings from streptozotocin-induced rat models of diabetes, an effect that was also detected with ipragliflozin in a similar mouse model [17]. However, because EMPA treatment in these studies also caused a large reduction in plasma glucose levels, it is impossible to interpret these data towards EMPA exerting direct vascular effects. Wang et al [18] reported that NHE activation in hyperglycaemic endothelial cells led to increased intracellular \(\text{Ca}^{2+}\) and reduced endothelial nitric oxide synthase levels and impaired relaxation of aortic rings from streptozotocin-induced rat models of diabetes, an effect that was also detected with ipragliflozin in a similar mouse model [17].
healthy hearts was already optimal and could not be improved by treatment with SGLT2i. Interestingly, a preliminary study in db/db mice found that EMPA administration acutely improved PCr/ATP [19]. In our experiments, we did notice a non-significant trend of increased O2 consumption in EMPA-treated hearts (p = 0.054), which may possibly indicate increased activation of mitochondrial energy metabolism.

We cannot explain why DAPA did not significantly induce vasodilation in healthy hearts. The non-significant results for DAPA in relation to vasodilation could in part be explained by the relatively low sample size. Here, we only studied the direct effects of SGLT2i for 30 min in isolated hearts. Chronic cardiac effects of SGLT2i may be studied in the future in in vivo models to translate and understand drug effects in individuals who use SGLT2 daily. Another limitation of this study is the lack of a diabetic model to investigate direct cardiac effects of SGLT2i. Nonetheless, the results in healthy cells and hearts suggest that these direct effects of SGLT2i may happen regardless of diabetes, opening the possibility to explore SGLT2i in other cardiac diseases where increased NHE activity is a driver of the disease, such as heart failure and hypertrophy. Thus, future research should also examine the effects of SGLT2i on cardiac physiology and metabolism in diabetic and failing hearts.

In conclusion, EMPA, DAPA and CANA all exhibit direct cardiac effects through NHE inhibition and [Na+]r reduction. EMPA and CANA, but not DAPA, induce coronary dilation of the intact heart.

Acknowledgements Some of the data were presented as an abstract at the 53rd EASD Annual Meeting in 2017.

Data availability The datasets generated and analysed in the current study are available from the corresponding author on reasonable request.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Duality of interest The authors declare that there is no duality of interest associated with this manuscript.

Contribution statement CAS, JWTF, MWH and NCW contributed to the analysis planning and interpretation of data, and reviewed and edited the manuscript. MJ and AK contributed to the acquisition of data and reviewed the manuscript. LU, AB, BB, RC and CJZ contributed to the conception and design, acquisition of data, and analysis and interpretation of data, and drafting or revising the critical intellectual content of the manuscript. All authors are responsible for the content and approved the final version. CJZ is guarantor of this work.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Reddy RPM, Inzucchi SE (2016) SGLT2 inhibitors in the management of type 2 diabetes. Endocrine 53:364–372
2. Zinnman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128
3. Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657
4. Baartscheer A, Schumacher CA, Wüst RCI et al (2017) Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia 60:568–573
5. Yokoyama H, Gunasegaram S, Harding SE, Avkiran M (2000) Sarcolemmal Na+/H+ exchanger activity and expression in human ventricular myocardium. J Am Coll Cardiol 36:534–540
6. Baartscheer A, Schumacher CA, Van Boreum MMGJ, Belteman CNW, Coronel R, Fiolet JWT (2003) Increased Na+/H+-exchange activity is the cause of increased [Na+] and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model. Cardiovasc Res 57:1015–1024
7. Despa S, Islam MA, Weber CR, Pogwizd SM, Bers DM (2002) Intracellular Na+ concentration is elevated in heart failure but Na/K pump function is unchanged. Circulation 105:2543–2548
8. Darmellah A, Baetz D, Prunier F, Tamaresille S (2007) Enhanced activity of the myocardial Na+/H+ exchanger contributes to left ventricular hypertrophy in the Goto–Kakizaki rat model of type 2 diabetes: critical role of Akt. Diabetologia 50:1335–1344
9. Lambert R, Srodulski S, Peng X et al (2015) Intracellular Na+ concentration ([Na+]r) is elevated in diabetic hearts due to enhanced Na+-glucose cotransport. J Am Heart Assoc 4:e002183
10. Scheen AJ (2014) Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol 10:647–663
11. Trott O, Olson A (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem 31:455–461
12. Pogwizd SM, Sipido KR, Verdonck F, Bers DM (2003) Intracellular Na in animal models of hypertrophy and heart failure: contractile function and arrhythmogenesis. Cardiovasc Res 57:887–896
13. Karmazyn M (2013) NHE-1: still a viable therapeutic target. J Mol Cell Cardiol 61:77–82
14. Baartscheer A, Hardzyenza M, Schumacher CA (2008) Chronic inhibition of the Na+/H+-exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodeling. Br J Pharmacol 154:1266–1275
15. Lacroix J, Poët M, Maehrel C, Counillon L (2004) A mechanism for the activation of the Na/H exchanger NHE-1 by cytoplasmic acidification and mitogens. EMBO Rep 5:91–96
16. Oelze M, Kröller-Schön S, Welshof P et al (2014) The sodium–glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One 9:1–13
17. Salim HM, Fukuda D, Yagi S, Soeki T, Shimabuku M, Sata M (2016) Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse. Front Cardiovasc Med 3:1–9
18. Wang S, Peng Q, Zhang J, Liu L (2008) Na+/H+ exchange is required for hyperglycaemia-induced endothelial dysfunction via calcium-dependent calpain. Cardiovasc Res 80:255–262
19. Abdurrahim D, Manders E, Nicolay K, Prompers J, Mayoux E (2017) The effect of a single dose of empagliflozin on cardiac energy status in diabetic mice. Diabetes 66;A125